• Novel EZH2 inhibitor JQ5 and BET-bromodomain inhibitor JQ1 reduce pulmonary dysfunction and blunt GC response in murine cGVHD.

  • Despite similar physiological impacts, JQ1 and JQ5 induce distinct transcriptional changes that independently disrupt the GC.

Despite advances in the field, chronic graft-versus-host-disease (cGVHD) remains a leading cause of morbidity and mortality following allogenic hematopoietic stem cell transplant. Because treatment options remain limited, we tested efficacy of anticancer, chromatin-modifying enzyme inhibitors in a clinically relevant murine model of cGVHD with bronchiolitis obliterans (BO). We observed that the novel enhancer of zeste homolog 2 (EZH2) inhibitor JQ5 and the BET-bromodomain inhibitor JQ1 each improved pulmonary function; impaired the germinal center (GC) reaction, a prerequisite in cGVHD/BO pathogenesis; and JQ5 reduced EZH2-mediated H3K27me3 in donor T cells. Using conditional EZH2 knockout donor cells, we demonstrated that EZH2 is obligatory for the initiation of cGVHD/BO. In a sclerodermatous cGVHD model, JQ5 reduced the severity of cutaneous lesions. To determine how the 2 drugs could lead to the same physiological improvements while targeting unique epigenetic processes, we analyzed the transcriptomes of splenic GCB cells (GCBs) from transplanted mice treated with either drug. Multiple inflammatory and signaling pathways enriched in cGVHD/BO GCBs were reduced by each drug. GCBs from JQ5- but not JQ1-treated mice were enriched for proproliferative pathways also seen in GCBs from bone marrow-only transplanted mice, likely reflecting their underlying biology in the unperturbed state. In conjunction with in vivo data, these insights led us to conclude that epigenetic targeting of the GC is a viable clinical approach for the treatment of cGVHD, and that the EZH2 inhibitor JQ5 and the BET-bromodomain inhibitor JQ1 demonstrated clinical potential for EZH2i and BETi in patients with cGVHD/BO.

1.
Greinix
HT
.
Chronic GVHD: progress in salvage treatment?
Blood.
2017
;
130
(
21
):
2237
-
2238
.
2.
Flowers
MED
,
Parker
PM
,
Johnston
LJ
, et al
.
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
.
Blood.
2002
;
100
(
2
):
415
-
419
.
3.
Lee
SJ
.
Have we made progress in the management of chronic graft-vs-host disease?
Best Pract Res Clin Haematol.
2010
;
23
(
4
):
529
-
535
.
4.
Socié
G
,
Stone
JV
,
Wingard
JR
, et al;
Late Effects Working Committee of the International Bone Marrow Transplant Registry
.
Long-term survival and late deaths after allogeneic bone marrow transplantation
.
N Engl J Med.
1999
;
341
(
1
):
14
-
21
.
5.
Lee
SJ
,
Klein
JP
,
Barrett
AJ
, et al
.
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
.
Blood.
2002
;
100
(
2
):
406
-
414
.
6.
Miklos
D
,
Cutler
CS
,
Arora
M
, et al
.
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
.
Blood.
2017
;
130
(
21
):
2243
-
2250
.
7.
Wolff
D
,
Gerbitz
A
,
Ayuk
F
, et al
.
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD
.
Biol Blood Marrow Transplant.
2010
;
16
(
12
):
1611
-
1628
.
8.
Jagasia
M
,
Lazaryan
A
,
Bachier
CR
, et al
.
ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease
.
J Clin Oncol.
2021
;
39
(
17
):
1888
-
1898
.
9.
Zeiser
R
,
Polverelli
N
,
Ram
R
, et al;
REACH3 Investigators
.
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
.
N Engl J Med.
2021
;
385
(
3
):
228
-
238
.
10.
Mawardi
H
,
Hashmi
SK
,
Elad
S
,
Aljurf
M
,
Treister
N
.
Chronic graft-versus-host disease: current management paradigm and future perspectives
.
Oral Dis.
2019
;
25
(
4
):
931
-
948
.
11.
Hildebrandt
GC
,
Fazekas
T
,
Lawitschka
A
, et al
.
Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
.
Bone Marrow Transplant.
2011
;
46
(
10
):
1283
-
1295
.
12.
Flynn
R
,
Paz
K
,
Du
J
, et al
.
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism
.
Blood.
2016
;
127
(
17
):
2144
-
2154
.
13.
Jagasia
M
,
Salhotra
A
,
Bachier
CR
, et al
.
KD025-208: a phase 2a study of KD025 for patients with chronic graft versus host disease (cGVHD) – pharmacodynamics (PD) and updated results
.
Blood.
2018
;
132
(
suppl 1
):
602
.
14.
Panoskaltsis-Mortari
A
,
Tram
KV
,
Price
AP
,
Wendt
CH
,
Blazar
BR
.
A new murine model for bronchiolitis obliterans post-bone marrow transplant
.
Am J Respir Crit Care Med.
2007
;
176
(
7
):
713
-
723
.
15.
Srinivasan
M
,
Flynn
R
,
Price
A
, et al
.
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans
.
Blood.
2012
;
119
(
6
):
1570
-
1580
.
16.
Flynn
R
,
Du
J
,
Veenstra
RG
, et al
.
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans
.
Blood.
2014
;
123
(
25
):
3988
-
3998
.
17.
Béguelin
W
,
Popovic
R
,
Teater
M
, et al
.
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation
.
Cancer Cell.
2013
;
23
(
5
):
677
-
692
.
18.
Velichutina
I
,
Shaknovich
R
,
Geng
H
, et al
.
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
.
Blood.
2010
;
116
(
24
):
5247
-
5255
.
19.
Czermin
B
,
Melfi
R
,
McCabe
D
,
Seitz
V
,
Imhof
A
,
Pirrotta
V
.
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites
.
Cell.
2002
;
111
(
2
):
185
-
196
.
20.
Cao
R
,
Wang
L
,
Wang
H
, et al
.
Role of histone H3 lysine 27 methylation in Polycomb-group silencing
.
Science.
2002
;
298
(
5595
):
1039
-
1043
.
21.
Boyer
LA
,
Plath
K
,
Zeitlinger
J
, et al
.
Polycomb complexes repress developmental regulators in murine embryonic stem cells
.
Nature.
2006
;
441
(
7091
):
349
-
353
.
22.
Lee
TI
,
Jenner
RG
,
Boyer
LA
, et al
.
Control of developmental regulators by Polycomb in human embryonic stem cells
.
Cell.
2006
;
125
(
2
):
301
-
313
.
23.
Bernstein
BE
,
Mikkelsen
TS
,
Xie
X
, et al
.
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
.
Cell.
2006
;
125
(
2
):
315
-
326
.
24.
Shin
DM
,
Liu
R
,
Wu
W
, et al
.
Global gene expression analysis of very small embryonic-like stem cells reveals that the Ezh2-dependent bivalent domain mechanism contributes to their pluripotent state
.
Stem Cells Dev.
2012
;
21
(
10
):
1639
-
1652
.
25.
Li
B
,
Chng
WJ
.
EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
.
J Hematol Oncol.
2019
;
12
(
1
):
118
.
26.
Villanueva
MT
.
Anticancer drugs: all roads lead to EZH2 inhibition
.
Nat Rev Drug Discov.
2017
;
16
(
4
):
239
.
27.
Tan
JZ
,
Yan
Y
,
Wang
XX
,
Jiang
Y
,
Xu
HE
.
EZH2: biology, disease, and structure-based drug discovery
.
Acta Pharmacol Sin.
2014
;
35
(
2
):
161
-
174
.
28.
Filippakopoulos
P
,
Qi
J
,
Picaud
S
, et al
.
Selective inhibition of BET bromodomains
.
Nature.
2010
;
468
(
7327
):
1067
-
1073
.
29.
Alqahtani
A
,
Choucair
K
,
Ashraf
M
, et al
.
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
.
Future Sci OA.
2019
;
5
(
3
):
FSO372
.
30.
Mele
DA
,
Salmeron
A
,
Ghosh
S
,
Huang
HR
,
Bryant
BM
,
Lora
JM
.
BET bromodomain inhibition suppresses TH17-mediated pathology
.
J Exp Med.
2013
;
210
(
11
):
2181
-
2190
.
31.
Gao
F
,
Yang
Y
,
Wang
Z
,
Gao
X
,
Zheng
B
.
BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF-κB activation
.
Cell Immunol.
2015
;
294
(
1
):
1
-
8
.
32.
Sun
Y
,
Wang
Y
,
Toubai
T
, et al
.
BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice
.
Blood.
2015
;
125
(
17
):
2724
-
2728
.
33.
Wang
D
,
Quiros
J
,
Mahuron
K
, et al
.
Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity
.
Cell Rep.
2018
;
23
(
11
):
3262
-
3274
.
34.
DuPage
M
,
Chopra
G
,
Quiros
J
, et al
.
The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation
.
Immunity.
2015
;
42
(
2
):
227
-
238
.
35.
Radojcic
V
,
Pletneva
MA
,
Yen
H-R
, et al
.
STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model
.
J Immunol.
2010
;
184
(
2
):
764
-
774
.
36.
Anderson
BE
,
McNiff
J
,
Yan
J
, et al
.
Memory CD4+ T cells do not induce graft-versus-host disease
.
J Clin Invest.
2003
;
112
(
1
):
101
-
108
.
37.
Zhang
H
,
Qi
J
,
Reyes
JM
, et al
.
Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer
.
Cancer Discov.
2016
;
6
(
9
):
1006
-
1021
.
38.
Pau
G
,
Fuchs
F
,
Sklyar
O
,
Boutros
M
,
Huber
W
.
EBImage – an R package for image processing with applications to cellular phenotypes
.
Bioinformatics.
2010
;
26
(
7
):
979
-
981
.
39.
Blazar
BR
,
Taylor
PA
,
McElmurry
R
, et al
.
Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer
.
Blood.
1998
;
92
(
10
):
3949
-
3959
.
40.
Baller
J
,
Kono
T
,
Herman
A
,
Zhang
YCURP
. A lightweight CLI framework to enable novice users to analyze sequencing datasets in parallel. ACM International Conference Proceeding Series.
2019
.
41.
Anders
S
.
Babraham bioinformatics. FastQC: a quality control tool for high throughput sequence data
.
Soil (Gottingen).
2010
;
5
(
1
).
42.
Bolger
AM
,
Lohse
M
,
Usadel
B
.
Trimmomatic: a flexible trimmer for Illumina sequence data
.
Bioinformatics.
2014
;
30
(
15
):
2114
-
2120
.
43.
Kim
D
,
Paggi
JM
,
Park
C
,
Bennett
C
,
Salzberg
SL
.
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
.
Nat Biotechnol.
2019
;
37
(
8
):
907
-
915
.
44.
Danecek
P
,
Bonfield
JK
,
Liddle
J
, et al
.
Twelve years of SAMtools and BCFtools
.
Gigascience.
2021
;
10
(
2
):
giab008
.
45.
Liao
Y
,
Smyth
GK
,
Shi
W
.
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
.
Bioinformatics.
2014
;
30
(
7
):
923
-
930
.
46.
Love
MI
,
Huber
W
,
Anders
S
.
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
.
Genome Biol.
2014
;
15
(
12
):
550
.
47.
Konze
KD
,
Ma
A
,
Li
F
, et al
.
An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1
.
ACS Chem Biol.
2013
;
8
(
6
):
1324
-
1334
.
48.
Miranda
TB
,
Cortez
CC
,
Yoo
CB
, et al
.
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
.
Mol Cancer Ther.
2009
;
8
(
6
):
1579
-
1588
.
49.
Sinha
RK
,
Flynn
R
,
Zaiken
M
, et al
.
Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells
.
Blood.
2019
;
134
(
9
):
776
-
781
.
50.
Reynaud-Gaubert
M
,
Thomas
P
,
Badier
M
, et al
.
Early detection of airway involvement in obliterative bronchiolitis after lung transplantation
.
Am J Respir Crit Care Med.
2012
;
161
(
6
):
1924
-
1929
.
51.
Sarantopoulos
S
,
Blazar
BR
,
Cutler
C
,
Ritz
J
.
B cells in chronic graft-versus-host disease
.
Biol Blood Marrow Transplant.
2015
;
21
(
1
):
16
-
23
.
52.
Liberzon
A
,
Birger
C
,
Thorvaldsdóttir
H
,
Ghandi
M
,
Mesirov
JP
,
Tamayo
P
.
The Molecular Signatures Database (MSigDB) hallmark gene set collection
.
Cell Syst.
2015
;
1
(
6
):
417
-
425
.
53.
Blazar
BR
,
Murphy
WJ
,
Abedi
M
.
Advances in graft-versus-host disease biology and therapy
.
Nat Rev Immunol.
2012
;
12
(
6
):
443
-
458
.
54.
Kamijo
H
,
Sugaya
M
,
Takahashi
N
, et al
.
BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines
.
Arch Dermatol Res.
2017
;
309
(
6
):
491
-
497
.
55.
Berdasco
M
,
Esteller
M
.
Aberrant epigenetic landscape in cancer: how cellular identity goes awry
.
Dev Cell.
2010
;
19
(
5
):
698
-
711
.
56.
Chen
H
,
Liu
H
,
Qing
G
.
Targeting oncogenic Myc as a strategy for cancer treatment
.
Signal Transduct Target Ther.
2018
;
3
(
1
):
5
.
57.
Mertz
JA
,
Conery
AR
,
Bryant
BM
, et al
.
Targeting MYC dependence in cancer by inhibiting BET bromodomains
.
Proc Natl Acad Sci USA.
2011
;
108
(
40
):
16669
-
16674
.
58.
Zuber
J
,
Shi
J
,
Wang
E
, et al
.
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
.
Nature.
2011
;
478
(
7370
):
524
-
528
.
59.
Stewart
HJS
,
Horne
GA
,
Bastow
S
,
Chevassut
TJT
.
BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
.
Cancer Med.
2013
;
2
(
6
):
826
-
835
.
60.
Dawson
MA
,
Prinjha
RK
,
Dittmann
A
, et al
.
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
.
Nature.
2011
;
478
(
7370
):
529
-
533
.
61.
Ehx
G
,
Fransolet
G
,
de Leval
L
, et al
.
Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects
.
OncoImmunology.
2017
;
6
(
5
):
e1314425
.
62.
Cooper
ML
,
Choi
J
,
Karpova
D
, et al
.
Azacitidine mitigates graft-versus-host disease via differential effects on the proliferation of T effectors and natural regulatory T cells in vivo
.
J Immunol.
2017
;
198
(
9
):
3746
-
3754
.
63.
Choi
SW
,
Braun
T
,
Henig
I
, et al
.
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
.
Blood.
2017
;
130
(
15
):
1760
-
1767
.
64.
Holtan
SG
,
Weisdorf
DJ
.
Vorinostat is victorious in GVHD prevention
.
Blood.
2017
;
130
(
15
):
1690
-
1691
.
65.
Choi
S
,
Reddy
P
.
HDAC inhibition and graft versus host disease
.
Mol Med.
2011
;
17
(
5-6
):
404
-
416
.
66.
Reddy
P
,
Maeda
Y
,
Hotary
K
, et al
.
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
.
Proc Natl Acad Sci USA.
2004
;
101
(
11
):
3921
-
3926
.
67.
Huang
Q
,
He
S
,
Tian
Y
, et al
.
Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice
.
Blood.
2017
;
129
(
20
):
2737
-
2748
.
68.
Alahmari
B
,
Cooper
M
,
Ziga
E
,
Ritchey
J
,
DiPersio
JF
,
Choi
J
.
Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation
.
PLoS One.
2018
;
13
(
11
):
e0207609
.
69.
Souroullas
GP
,
Jeck
WR
,
Parker
JS
, et al
.
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation
.
Nat Med.
2016
;
22
(
6
):
632
-
640
.
70.
Tan
J
,
Yang
X
,
Zhuang
L
, et al
.
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
.
Genes Dev.
2007
;
21
(
9
):
1050
-
1063
.
71.
Du
J
,
Paz
K
,
Flynn
R
, et al
.
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production
.
Blood.
2017
;
129
(
18
):
2570
-
2580
.
72.
Paz
K
,
Flynn
R
,
Du
J
, et al
.
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease
.
Blood.
2019
;
133
(
1
):
94
-
99
.
73.
Dubovsky
JA
,
Flynn
R
,
Du
J
, et al
.
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
.
J Clin Invest.
2014
;
124
(
11
):
4867
-
4876
.
74.
Balakrishnan
A
,
Gloude
N
,
Sasik
R
,
Ball
ED
,
Morris
GP
.
Proinflammatory dual receptor T cells in chronic graft-versus-host disease
.
Biol Blood Marrow Transplant.
2017
;
23
(
11
):
1852
-
1860
.
75.
Santos E Sousa
P
,
Ciré
S
,
Conlan
T
, et al
.
Peripheral tissues reprogram CD8+ T cells for pathogenicity during graft-versus-host disease
.
JCI Insight.
2018
;
3
(
5
):
97011
.
76.
Poe
JC
,
Zhang
D
,
Xie
J
, et al
.
Single-cell RNA-seq identifies potentially pathogenic B cell populations that uniquely circulate in patients with chronic Gvhd
.
Blood.
2019
;
134
(
suppl 1
):
874
.
77.
Zhong
H
,
Liu
Y
,
Xu
Z
, et al
.
TGF-β-induced CD8+CD103+ regulatory T cells show potent therapeutic effect on chronic graft-versus-host disease lupus by suppressing B cells
.
Front Immunol.
2018
;
9
:
35
.
78.
Deng
R
,
Hurtz
C
,
Song
Q
, et al
.
Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease
.
Nat Commun.
2017
;
8
(
1
):
978
.
79.
Calado
DP
,
Sasaki
Y
,
Godinho
SA
, et al
.
The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers
.
Nat Immunol.
2012
;
13
(
11
):
1092
-
1100
.
80.
Klein
U
,
Dalla-Favera
R
.
Germinal centres: role in B-cell physiology and malignancy
.
Nat Rev Immunol.
2008
;
8
(
1
):
22
-
33
.
You do not currently have access to this content.

Sign in via your Institution